Articles related to CLINICAL STUDY

Lecanemab is a humanized IgG1 monoclonal antibody that binds to some forms of amyloid. In this study approximately 1,800 participants age 50-90 with dementia and imaging evidence of amyloid deposits were randomized to biweekly IV lecanemab or placebo. After 18 months, the lecanemab group showed reductions in brain amyloid and moderately less decline on measures of cognition and function.

The study looks at outcomes of people who came down with COVID during the infection’s first wave. Fatigue, pain, and memory loss were the most common persistent symptoms, in that order.

In a recently published prospective cohort study, a third dose of the BioNTech Pfizer vaccine yielded a sustained immunologic response. But response to a fourth was much smaller and was gone completely by 13 weeks, providing only a short-term benefit over the third dose. A fourth dose should therefore be timed based on disease waves or be provided seasonally, like the influenza vaccine.

The findings of this study are similar to results from in small human post-mortem study and could provide a pathological explanation for the subjective complaint of long-COVID “brain fog.” Using a mouse model to explore how mild respiratory infections with COVID could lead to neuroinflammation and subsequent brain damage, investigators found signs of central neuroinflammation after clearance of the virus. There is an accompanying case presentation.

In a study originally published in British Journal of Sports Medicine, a sample of nearly 100,000 adults showed that after making adjustments for other activity, weight training was associated with a 9% decline in CVD mortality. A separate study published in Medicine & Science in Sports & Exercise showed a lower risk of colorectal cancer in adults who lifted weights.

Looking at 2,500 case patients mapped to more than 45,000 controls, the hazard ratio for all thyroid cancers in GLP-1 users was 1.46. The hazard ratio for developing thyroid cancer with DPP-4 inhibitors was 1.1. GLP-1 receptors are present in normal and cancerous thyroid cells.